TARS Tarsus Pharmaceuticals, Inc. Stock Quote

TARS [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	17.00%	Shs Outstand	21.05M	Perf Week	-18.50%
Market Cap	644.34M	Forward P/E	-	EPS next Y	-2.62	Insider Trans	0.00%	Shs Float	13.52M	Perf Month	-18.24%
Income	-	PEG	-	EPS next Q	-0.66	Inst Own	61.70%	Short Float	2.58%	Perf Quarter	32.63%
Sales	-	P/S	-	EPS this Y	-254.10%	Inst Trans	-	Short Ratio	3.77	Perf Half Y	-
Book/sh	-	P/B	-	EPS next Y	-14.90%	ROA	-	Target Price	41.50	Perf Year	-
Cash/sh	4.10	P/C	7.47	EPS next 5Y	-	ROE	-	52W Range	15.32 - 63.69	Perf YTD	-25.94%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-51.94%	Beta	-
Dividend %	-	Quick Ratio	14.50	Sales past 5Y	-	Gross Margin	-	52W Low	99.74%	ATR	3.57
Employees	12	Current Ratio	14.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	34.98	Volatility	12.37% 10.03%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.47	Prev Close	33.13
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	92.49K	Price	30.61
Recom	1.20	SMA20	-18.88%	SMA50	-24.34%	SMA200	-8.32%	Volume	43,175	Change	-7.61%

Nov-10-20

Initiated

Raymond James

Strong Buy

$39

Nov-10-20

Initiated

Ladenburg Thalmann

Buy

$42

Nov-10-20

Initiated

Jefferies

Buy

$35

Nov-10-20

Initiated

BofA Securities

Buy

$33

Jan-19-21 08:30AM	Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel GlobeNewswire
Jan-18-21 08:43AM	Tarsus Pharmaceuticals (NASDAQ:TARS) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Jan-07-21 09:24AM	Tarsus Pharmaceuticals, Inc. Appoints Dianne Whitfield as Chief Human Resources Officer GlobeNewswire +5.23%
Jan-05-21 05:00PM	Tarsus Pharmaceuticals, Inc. to Present at the 2021 ICR Virtual Conference GlobeNewswire
Dec-23-20 07:00AM	Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03 GlobeNewswire
Dec-21-20 07:00AM	Tarsus Pharmaceuticals, Inc. Announces Inclusion in the Russell 3000® Index and Russell 2000® Index GlobeNewswire -11.00%
Nov-19-20 03:24PM	Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors GlobeNewswire +7.78%
Nov-13-20 07:35PM	Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference GlobeNewswire +10.16%
Oct-20-20 04:05PM	Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional Shares GlobeNewswire
Oct-16-20 06:05PM	Hearing-Aid Maker Eargo Soars 87% in Its First Trading Day Barrons.com
Oct-15-20 08:35PM	Tarsus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering GlobeNewswire

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience